User:Mr. Ibrahem/Cabozantinib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Cabozantinib
Clinical data
Pronunciationka" boe zan' ti nib[1]
Trade namesCometriq, Cabometyx, others
Other namesXL184, BMS907351
AHFS/Drugs.comMonograph
MedlinePlusa613015
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classTyrosine kinase inhibitor[3]
Legal status
Legal status
Pharmacokinetic data
Protein binding≥99.7%
MetabolismLiver (CYP3A4-mediated)
Elimination half-life110 hours
ExcretionFeces (54%), urine (27%)
Identifiers
  • N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Chemical and physical data
FormulaC28H24FN3O5
Molar mass501.514 g·mol−1
3D model (JSmol)
  • O=C(C1(CC1)C(NC2=CC=C(F)C=C2)=O)NC(C=C3)=CC=C3OC4=C(C=C(OC)C(OC)=C5)C5=NC=C4
  • InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)
  • Key:ONIQOQHATWINJY-UHFFFAOYSA-N

Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is a medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.[8][3] It is used in advanced disease or cases which have failed other treatments.[3] It is taken by mouth.[3]

Common side effects include diarrhea, tiredness, high blood pressure, nausea, and weight loss.[3] Other side effects may include bleeding, fistula, blood clots, liver problems, and reversible posterior leukoencephalopathy syndrome.[3] Use in pregnancy may harm the baby.[3] It is a tyrosine kinase inhibitor of MET, VEGFR, and AXL.[3]

Cabozantinib was approved for medical use in the United States in 2012 and Europe in 2014.[3][8] In the United Kingdom a dose of 60 mg a day for a month costs about £5,150 as of 2021.[10] This amount in the United States costs about 22,600 USD.[11]

References[edit]

  1. ^ "Cabozantinib". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 11 January 2022. Retrieved 29 December 2021.
  2. ^ "Cabozantinib Use During Pregnancy". Drugs.com. 30 March 2020. Archived from the original on 3 December 2020. Retrieved 23 September 2020.
  3. ^ a b c d e f g h i j k "DailyMed - CABOMETYX- cabozantinib tablet". dailymed.nlm.nih.gov. Archived from the original on 29 October 2020. Retrieved 29 December 2021.
  4. ^ "Cabozantinib tablet (Cabometyx) UK Summary of Product Characteristics". UK Electronic Medicines Compendium. September 2016. Archived from the original on 2019-06-23. Retrieved 2021-10-05.
  5. ^ "Cabozantinib capsule (Cometriq) UK Summary of Product Characteristics (SPC) - (eMC)". UK Electronic Medicines Compendium. November 2016. Archived from the original on 2019-06-23. Retrieved 2021-10-05.
  6. ^ "Cabometyx- cabozantinib tablet". DailyMed. 21 July 2020. Archived from the original on 29 October 2020. Retrieved 23 September 2020.
  7. ^ "Cometriq- cabozantinib kit Cometriq- cabozantinib capsule". DailyMed. 11 February 2020. Archived from the original on 29 October 2020. Retrieved 23 September 2020.
  8. ^ a b c d "Cometriq EPAR". European Medicines Agency (EMA). Archived from the original on 2 October 2018. Retrieved 23 September 2020.
  9. ^ "Cabometyx EPAR". European Medicines Agency (EMA). Archived from the original on 4 August 2020. Retrieved 23 September 2020.
  10. ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1017. ISBN 978-0857114105.
  11. ^ "Cabometyx Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 4 March 2021. Retrieved 29 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Cabozantinib&oldid=1211442937"